Track topics on Twitter Track topics that are important to you
Response rates with the novel biologic that targets IL-23 are strong, even among obese patients, and the dosing interval is attractive, but the treatment field for plaque psoriasis is already crowded.
Medscape Medical News
Original Article: Risankizumab Effective for Moderate to Severe PsoriasisNEXT ARTICLE
Obesity is the condition in which excess fat has accumulated in the body (mostly in subcutaneous tissues). clinical obesity is considered to be present when a person has a BMI of over 30 (Oxford Dictionary of Medicine). It is becoming increasing common i...
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...